|China Shineway Pharmaceutical Group Limited -- Hong Kong Stock|| |
HKD 7.14 0.03 0.42%
Deputy General Manager
Mr. Wang Qinli serves as Deputy General Manager of China Shineway Pharmaceutical Group Ltd. He graduated from Henan Chinese Medical Institute with a bachelor degree in Chinese medicine in 1986. Prior to joining the Group Mr. Wang spent 10 years from 1986 to 1996 working in technology and new medicine research at a pharmaceutical manufacturer in Henan Province the PRC where he reached the post of Head of New Medicine Research and Head of Technology Department. Mr. Wang joined the Group in 1996 as manager of the research and development department and then was promoted to Deputy General Manager in 2003 responsible for overseeing the Groups production management and technology development.
Age: 51 Executive Since 2003
86 311 8803 0066 http://www.shineway.com
The company has return on total asset (ROA)
of 4.76 %
which means that it generated profit of $4.76 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 8.98 %
meaning that it generated $8.98 on every $100 dollars invested by stockholders.
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and trading of OTC Chinese pharmaceutical solutions in the People?s Republic of China and Hong Kong. China Shineway Pharmaceutical Group Limited (2877) is traded on Hong Kong Stock Exchange in Hong Kong. It is located in Shijiazhuang, and employs 4,110 people.